Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2025 09:08 ET | Source: Erasca, Inc.

Erasca to Present at the 8th Annual Evercore Healthcare Conference

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
November 12, 2025 16:01 ET | Source: Erasca, Inc.

Erasca Reports Third Quarter 2025 Business Updates and Financial Results

U.S. composition of matter patent protection through 2043 for potential best-in-class pan-RAS molecular glue ERAS-0015 Strengthened scientific leadership with promotion of Robert Shoemaker,...
November 06, 2025 08:00 ET | Source: Erasca, Inc.

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043 Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001...
November 04, 2025 08:00 ET | Source: Erasca, Inc.

Erasca to Present at Upcoming Conferences in November

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
September 02, 2025 08:00 ET | Source: Erasca, Inc.

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
August 12, 2025 16:01 ET | Source: Erasca, Inc.

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust...
June 02, 2025 08:00 ET | Source: Erasca, Inc.

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs...
May 29, 2025 08:00 ET | Source: Erasca, Inc.

Erasca to Present at Upcoming Investor Conferences in June

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
May 13, 2025 16:05 ET | Source: Erasca, Inc.

Erasca Reports First Quarter 2025 Business Updates and Financial Results

Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 ...
May 13, 2025 08:00 ET | Source: Erasca, Inc.

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful...